Yahoo! Finance Search - Finance Home - Yahoo! - Help

Saturday, August 29 2015 2:13am ET - U.S. Markets Closed.
Industry Center - Biotechnology
Industry Center > Biotechnology > News
More On This Industry
· Summary
News
·Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
 
Biotechnology News
Latest News
Friday, Aug 28, 2015
·SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Northwest Biotherapeutics, Inc. to Contact the Firm
Marketwire - Fri 10:10 pm ET
·AVALANCHE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Avalanche Biotechnologies, Inc. -- AAVL
PR Newswire - Fri 10:00 pm ET
·72-Hour Deadline Alert: Law Offices of Howard G. Smith Reminds Investors of August 31, 2015 Lead Plaintiff Deadline in the Class Action Lawsuit Against Celladon Corp.
Business Wire - Fri 8:58 pm ET
·3 Battleground Biotech Stocks I Would Avoid at All Costs
at Motley Fool - Fri 5:15 pm ET
·Why Ariad Pharmaceuticals Rocketed More Than 40% Higher Today
at Motley Fool - Fri 4:43 pm ET
·‚ÄčAmgen wins FDA approval for cholesterol drug Repatha
at bizjournals.com - Fri 4:10 pm ET
·Can Novavax Inc.'s Stock Inoculate Your Portfolio From More Market Mayhem?
at Motley Fool - Fri 4:03 pm ET
·Gilead & Amgen Account for Nearly 75% of the Biotech Profit Pool
at Barrons.com - Fri 3:34 pm ET
·Investor lawsuit against cancer immunotherapy company highlights hype around science
at bizjournals.com - Fri 2:30 pm ET
·Baxalta in talks to buy hematology-oncology specialist -Bloomberg
Reuters - Fri 2:23 pm ET
·3 Biotech Stocks Bucking the Stock Market Crash
at Motley Fool - Fri 2:02 pm ET
·Baxalta in talks to buy U.S. hematology-oncology specialist - Bloomberg
Reuters - Fri 1:31 pm ET
·Amgen v. Regeneron: Everyone Wins?
at Barrons.com - Fri 12:12 pm ET
·How Amgen Can Disrupt the Market for Cholesterol Drugs
- Fri 10:25 am ET
·Opexa Therapeutics to Present at September Conferences
Business Wire - Fri 9:00 am ET
·Time to Buy Amgen After Newly Approved Drug?
at TheStreet.com - Fri 8:37 am ET
·BioTime Management to Present at Rodman & Renshaw 17th Annual Global Investment Conference
Business Wire - Fri 8:30 am ET
·PRESS DIGEST- New York Times business news - August 28
Reuters - Fri 3:05 am ET
·SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Biogen Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit -- BIIB
GlobeNewswire - Fri 1:13 am ET
Thursday, Aug 27, 2015
·Amgen wins approval for second biotech cholesterol drug
AP - Thu 9:10 pm ET
More Latest News...
  

RSS Feeds

Add headlines to your
personalized My Yahoo Page
( About My Yahoo and RSS )

Biotechnology Headlines
More Finance RSS Feeds


Copyright © 2015 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2015 Morningstar, Inc. All Rights Reserved. Company information © 2015 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2015, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?